Wenge Xing

机构：Tianjin Medical University Cancer Institute and Hospital, National Center for AIDS/STD Control and Prevention,China CDC · ORCID：0000-0003-3882-2934

发表论文 75 篇 · 总被引 1485 次 · h-index 18

代表论文

• Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001) (2023 · Signal Transduction and Targeted Therapy · 被引 296)
• Hepatic arterial infusion chemotherapy combined with anti-PD-1/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study (2023 · Frontiers in Immunology · 被引 51)
• TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma. (2022 · Journal of Clinical Oncology · 被引 28)
• Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial (2024 · Neoplasma · 被引 22)
• Donafenib and sintilimab combined with hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma: a prospective, single-arm phase II trial (DoHAICs study) (2025 · EClinicalMedicine · 被引 11)
• Conversion of initially unresectable hepatocellular carcinoma (HCC) with triple-combination therapy (lenvatinib, anti-PD-1 antibodies, and transarterial therapy): A retrospective analysis. (2022 · Journal of Clinical Oncology · 被引 11)